JNPMEDI succeeded in attracting 14 billion won worth of Series A investment.
JNPMEDI
JNPMEDI, a medical data platform company, announced on the 22nd that it has successfully completed attracting 14 billion won worth of Series A investment. It is the first achievement in 10 months since it received a seed investment of 2 billion won in January this year, and the cumulative investment amount reaches 16 billion won.
Succeeded in attracting 14 billion won worth of Series A investment
JNPMEDI, a medical data platform company, announced on the 22nd that it has successfully completed attracting 14 billion won worth of Series A investment. It is the first achievement in 10 months since it received a seed investment of 2 billion won in January this year, and the cumulative investment amount reaches 16 billion won.
JNPMEDI 14 billion won series A funding has been completed. Accumulated investment of 16 billion won.
Pavilion Capital, a growth investment subsidiary of Singapore's largest sovereign wealth fund Temasek, participates as a lead investor. Kakao Ventures, Murex Partners, Ajou IB Investment, Gentium Partners, etc. are drawing attention as they reinvest all of them following their initial investments.
This series A funding was led by Pavilion Capital, a growth investment subsidiary of Temasek, Singapore's largest sovereign wealth fund, and it is noteworthy that Kakao Ventures, Murex Partners, Ajou IB Investment, and Gentium Partners, who have been together as early investors, participated in follow-up investments. It is noteworthy that all existing institutional investors have reinvested.
JNPMEDI, established in July 2020, is a leading IT-based clinical trial data solution platform such as cloud and blockchain. The clinical trial field, which has been less digitized than other fields, is an area with high demand for innovative technologies and is considered a promising industry with abundant growth potential. In line with this, JNPMEDI has attracted attention as a game changer in the Decentralized Clinical Trials (DCT) market by developing its own solution for clinical trial data management platform "Maven Clinical Cloud" that can be applied to various medical areas such as pharmaceuticals, bio, digital treatments, and digital medical devices.
Based on this investment attraction, JNPMEDI plans to upgrade its products and enter the global market in earnest. First, it aims to be reborn as a professional software provider that presents global standards in the clinical market by significantly strengthening data infrastructure and internal R&D organizations, strengthening cloud-based service stability, and upgrading software-as-a-service (SaaS) technology.